- Home
- KNSA vs WD Comparison
KNSA vs WD Comparison
Compare KNSA & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- WD
- Stock Information
- Founded
- KNSA 2015
- WD 1937
- Country
- KNSA United Kingdom
- WD United States
- Employees
- KNSA N/A
- WD N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- WD Finance: Consumer Services
- Sector
- KNSA Health Care
- WD Finance
- Exchange
- KNSA Nasdaq
- WD Nasdaq
- Market Cap
- KNSA 2.6B
- WD 2.9B
- IPO Year
- KNSA 2018
- WD 2010
- Fundamental
- Price
- KNSA $38.51
- WD N/A
- Analyst Decision
- KNSA Strong Buy
- WD Buy
- Analyst Count
- KNSA 7
- WD 1
- Target Price
- KNSA $44.00
- WD $95.00
- AVG Volume (30 Days)
- KNSA 392.4K
- WD 228.9K
- Earning Date
- KNSA 10-28-2025
- WD 11-06-2025
- Dividend Yield
- KNSA N/A
- WD 3.37%
- EPS Growth
- KNSA N/A
- WD 25.06
- EPS
- KNSA 0.07
- WD 3.24
- Revenue
- KNSA $529,332,000.00
- WD $1,111,017,000.00
- Revenue This Year
- KNSA $37.21
- WD $18.16
- Revenue Next Year
- KNSA $12.07
- WD $5.63
- P/E Ratio
- KNSA $582.26
- WD $24.57
- Revenue Growth
- KNSA 56.18
- WD 15.06
- 52 Week Low
- KNSA $17.82
- WD $64.48
- 52 Week High
- KNSA $39.12
- WD $118.19
- Technical
- Relative Strength Index (RSI)
- KNSA 64.65
- WD 41.09
- Support Level
- KNSA $37.69
- WD $80.20
- Resistance Level
- KNSA $38.83
- WD $86.38
- Average True Range (ATR)
- KNSA 0.95
- WD 2.06
- MACD
- KNSA 0.00
- WD -0.67
- Stochastic Oscillator
- KNSA 79.11
- WD 2.71
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About WD Walker & Dunlop Inc
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.